Jaume Roquer1, Rosa Maria Vivanco-Hidalgo2, Lluís L Prats-Sánchez2, Alejandro Martínez-Domeño2, Daniel Guisado-Alonso2, Elisa Cuadrado-Godia2, Eva Giralt Steinhauer2, Jordi Jiménez-Conde2, Ana Rodríguez-Campello2, Joan Martí-Fàbregas2, Angel Ois2. 1. From the Servei de Neurologia (J.R., R.M.V.-H., E.C.-G., E.G.S., J.J.-C., A.R.-C., A.O.), IMIM-Hospital del Mar; Departament de Medicina (J.R., E.G.S., J.J.-C., A.R.-C., A.O.), Universitat Autònoma de Barcelona; Servei de Neurologia (L.L.P.-S., A.M.-D., D.G.-A.), Hospital de Sant Pau; and DCEXS (E.C.-G., J.M.-F.), Universitat Pompeu Fabra, Barcelona, Spain. jroquer@parcdesalutmar.cat. 2. From the Servei de Neurologia (J.R., R.M.V.-H., E.C.-G., E.G.S., J.J.-C., A.R.-C., A.O.), IMIM-Hospital del Mar; Departament de Medicina (J.R., E.G.S., J.J.-C., A.R.-C., A.O.), Universitat Autònoma de Barcelona; Servei de Neurologia (L.L.P.-S., A.M.-D., D.G.-A.), Hospital de Sant Pau; and DCEXS (E.C.-G., J.M.-F.), Universitat Pompeu Fabra, Barcelona, Spain.
Abstract
OBJECTIVE: To analyze the clinical differences between patients with primary intracerebral hemorrhage (ICH) with and without atrial fibrillation (AF) and assess whether the effect of the antithrombotic pretreatment on outcome is modified by the presence of AF. METHODS: In this prospective observational study, researchers from 2 university hospitals included 1,106 consecutive patients with ICH. Clinical characteristics were described and stratified by presence of AF. In-hospital and 3-month mortality and 3-month disability were analyzed, considering antithrombotic pretreatment (none, antiplatelets, or oral anticoagulants) and AF (yes/no). RESULTS: AF was present in 21.9% of primary ICH cases. Patients with AF-ICH were older, with more vascular risk factors, more antithrombotic pretreatment, higher clinical severity, higher hematoma volume, and higher in-hospital and 3-month mortality. Do-not-resuscitate orders were applied more frequently in AF-ICH cases. After 2 different adjustment models, mortality remained significantly higher in patients with AF-ICH. However, after introducing previous antithrombotic treatment in the model, the adjusted odds ratio for 3-month mortality was 1.45 (95% confidence interval 0.74-2.85, p = 0.284) for patients with AF-ICH compared with non-AF cases. AF modified the effect of antithrombotic pretreatment on in-hospital (p int = 0.077) and 3-month mortality (p int = 0.008). Among patients without AF, antithrombotic pretreatment increased mortality; no effect was observed in patients with AF-ICH. CONCLUSIONS: Patients with AF and ICH had increased mortality; however, AF had no independent effect on mortality after adjustment for antithrombotic pretreatment. Conversely, antithrombotic pretreatment had a deleterious effect on outcome in patients with ICH without AF, but no detectable effect in patients with AF with ICH.
OBJECTIVE: To analyze the clinical differences between patients with primary intracerebral hemorrhage (ICH) with and without atrial fibrillation (AF) and assess whether the effect of the antithrombotic pretreatment on outcome is modified by the presence of AF. METHODS: In this prospective observational study, researchers from 2 university hospitals included 1,106 consecutive patients with ICH. Clinical characteristics were described and stratified by presence of AF. In-hospital and 3-month mortality and 3-month disability were analyzed, considering antithrombotic pretreatment (none, antiplatelets, or oral anticoagulants) and AF (yes/no). RESULTS:AF was present in 21.9% of primary ICH cases. Patients with AF-ICH were older, with more vascular risk factors, more antithrombotic pretreatment, higher clinical severity, higher hematoma volume, and higher in-hospital and 3-month mortality. Do-not-resuscitate orders were applied more frequently in AF-ICH cases. After 2 different adjustment models, mortality remained significantly higher in patients with AF-ICH. However, after introducing previous antithrombotic treatment in the model, the adjusted odds ratio for 3-month mortality was 1.45 (95% confidence interval 0.74-2.85, p = 0.284) for patients with AF-ICH compared with non-AF cases. AF modified the effect of antithrombotic pretreatment on in-hospital (p int = 0.077) and 3-month mortality (p int = 0.008). Among patients without AF, antithrombotic pretreatment increased mortality; no effect was observed in patients with AF-ICH. CONCLUSIONS:Patients with AF and ICH had increased mortality; however, AF had no independent effect on mortality after adjustment for antithrombotic pretreatment. Conversely, antithrombotic pretreatment had a deleterious effect on outcome in patients with ICH without AF, but no detectable effect in patients with AF with ICH.
Authors: Martina B Goeldlin; Bernhard M Siepen; Madlaine Mueller; Bastian Volbers; Werner Z'Graggen; David Bervini; Andreas Raabe; Nikola Sprigg; Urs Fischer; David J Seiffge Journal: Eur Stroke J Date: 2021-11-16